-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Explore the new world---standardized curriculum "Prostate Cancer Standardized Diagnosis and Treatment College" project is sponsored by the Beijing Medical Award Foundation, guided by the Chinese Anti-Cancer Association Urology and Andrology Reproductive Tumor Committee, and Yimaitong fully supports it.
Among them, the "Prostate Cancer Standardized Diagnosis and Treatment Course" aims to promote and promote the knowledge of standardized diagnosis and treatment of prostate cancer, and improve the academic level and professional skills in the field of prostate cancer across the country.
The fourth "Prostate Cancer Standardized Diagnosis and Treatment Course" The fourth period is "Prostate Cancer Molecular Typing and Precision Treatment" brought by Professor Zeng Hao from West China Hospital of Sichuan University: Click to watch the highlights video! Highlights Video Prostate cancer is a group of diseases with strong heterogeneity.
The survival time, treatment efficacy and survival prognosis of different prostate cancer patients are quite different.
Refining the evolutionary path of prostate cancer and the way of genetic modification, and adopting a precise and individualized treatment model, may further improve the survival benefits of patients.
So, what is the difference between the tumor progression and genetic changes of prostate cancer at different disease stages? What is the impact of molecular classification of prostate cancer on clinical treatment options for localized prostate cancer/metastatic hormone-sensitive prostate cancer (mHSPC)? What is the relationship between the molecular classification of prostate cancer and the decision-making of clinical treatment of metastatic castration-resistant prostate (mCRPC)? This issue of "Molecular Typing and Precision Treatment of Prostate Cancer" will discuss and share these topics in detail, aiming to promote clinical in-depth understanding of the evolutionary mechanism of prostate cancer and continuous exploration of precise and individualized treatment.
To watch the full video, please
Among them, the "Prostate Cancer Standardized Diagnosis and Treatment Course" aims to promote and promote the knowledge of standardized diagnosis and treatment of prostate cancer, and improve the academic level and professional skills in the field of prostate cancer across the country.
The fourth "Prostate Cancer Standardized Diagnosis and Treatment Course" The fourth period is "Prostate Cancer Molecular Typing and Precision Treatment" brought by Professor Zeng Hao from West China Hospital of Sichuan University: Click to watch the highlights video! Highlights Video Prostate cancer is a group of diseases with strong heterogeneity.
The survival time, treatment efficacy and survival prognosis of different prostate cancer patients are quite different.
Refining the evolutionary path of prostate cancer and the way of genetic modification, and adopting a precise and individualized treatment model, may further improve the survival benefits of patients.
So, what is the difference between the tumor progression and genetic changes of prostate cancer at different disease stages? What is the impact of molecular classification of prostate cancer on clinical treatment options for localized prostate cancer/metastatic hormone-sensitive prostate cancer (mHSPC)? What is the relationship between the molecular classification of prostate cancer and the decision-making of clinical treatment of metastatic castration-resistant prostate (mCRPC)? This issue of "Molecular Typing and Precision Treatment of Prostate Cancer" will discuss and share these topics in detail, aiming to promote clinical in-depth understanding of the evolutionary mechanism of prostate cancer and continuous exploration of precise and individualized treatment.
To watch the full video, please
